Mast cell tumors are the most common malignant skin tumor in dogs. Welfare management requires accurate grading, appropriate treatment, and quality of life support throughout.
The welfare experience of dogs with mast cell tumors varies enormously by grade. Low-grade tumors are often surgically curable with minimal impact on quality of life, while high-grade tumors carry poor prognoses and may cause systemic welfare problems through histamine release. Accurate grading via fine needle aspirate cytology and surgical biopsy is essential for welfare-appropriate treatment planning.
Histamine effects from MCT degranulation can cause vomiting, intestinal ulceration, and anaphylaxis. Management with H2 blockers (famotidine, omeprazole) is a welfare-critical component of MCT care, particularly around surgery when manipulation of the tumor can trigger degranulation.
Surgical excision under appropriate anesthesia and with good pain management is standard of care. The need for wide surgical margins can require cosmetically significant surgery, but most dogs tolerate and recover well. For dogs with advanced or inoperable disease, targeted therapy with toceranib (Palladia) has welfare-preserving effects through disease stabilization, though the drug itself can cause gastrointestinal side effects requiring monitoring.